Leukemia Research
Volume 34, Issue 4 , Pages 471-474 , April 2010

Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients

Received 2 May 2009 ,Revised 12 July 2009 ,Accepted 13 July 2009.

References 

  1. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–172
  2. Jagannath S, Barlogie B, Berenson JR, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008;143:537–540
  3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617
  4. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498
  5. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557–3560
  6. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776–783
  7. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasoneas induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91:1498–1505
  8. Harousseau JL, Mathiot C, Attal M, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated from IFM 2005/01 trial. J Clin Oncol. 2008;26:[8505 abstr]
  9. Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol. 2008;141:512–516
  10. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase II study. Blood. 2006;108:2165–2172
  11. San Miguel J, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917
  12. Rosinol L, Oriol A, Mateos MV, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma. Efficacy and clinical implication of tumor response kinetics. J Clin Oncol. 2007;25:4452–4458
  13. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113–3120
  14. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of dose modification guideline. Br J Hematol. 2009;144:895–903
  15. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single centre experience and review of the literature. Cancer. 2007;110:1042–1049
  16. Caravita T, Petrucci MT, Spagnoli A, et al. Neuropathy in multiple myeloma patients treated with bortezomib: a multicenter experience. Blood. 2007;110:[Abstract 4823]
  17. El-Cheikh J, Stoppa AM, Bouabdallah R, et al. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advance multiple myeloma. Clin Lymph Myel. 2008;8:146–152
  18. Argyriou A, Iconomou G, Kalofonos H, et al. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112:1593–1599
  19. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological study in the rat. Exp Neurol. 2007;204:317–325
  20. Cata JP, Weng HR, Burton AW, et al. Quantitative sensory findings in patients with bortezomib induced pain. J Pain. 2007;8:296–306
  21. Ravaglia S, Corso A, Piccolo G, et al. Immune-mediated neuropathies in multiple myeloma patients treated with bortezomib. Clin Neurophysiol. 2008;119:2507–2512
  22. Borrello I, Ferguson A, Huff CA, et al. Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma: efficacy and neurotoxicity. Blood. 2006;108:[Abstr 3528]

PII: S0145-2126(09)00365-8

doi: 10.1016/j.leukres.2009.07.022

Leukemia Research
Volume 34, Issue 4 , Pages 471-474 , April 2010

Article Tools